This note updates on our Buysider Coverage: The US OSG results from ZBH and SYK were all well ahead as previewed, demonstrating that Advan's data has high efficacy in Med Tech. Q3 has started strongly.Our top-line estimates (based on our cellphone activity) were on the mark for DNR and DGX. Agilent (ticker:A) should be in line with consensus.





